Login to Your Account

Strike Two: FDA Denies Cell Therapeutics' Pixantrone Appeal

By Catherine Shaffer

Wednesday, May 4, 2011
A year after the FDA rejected Cell Therapeutics Inc.'s (CTI) pixantrone application for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL), the Office of New Drugs (OND) has denied an appeal request from CTI, which claimed the drug showed efficacy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription